Solaris Vaccines, Inc.
Solaris Vaccines, Inc. was established in 2021 with the mission to develop rapid, safe, and effective vaccines for global health challenges. They utilize the innovative SolaVAX™ platform, which employs riboflavin and UV light to inactivate pathogens, offering a faster and potentially safer alternative to traditional vaccine methods. The company's vision is to address the limitations of current vaccine development and manufacturing processes, providing flexible, low-cost, and globally distributable vaccines, including for emergent threats like COVID-19 and Dengue.
Industries
Nr. of Employees
small (1-50)
Products
Photochemical inactivated vaccine platform
A platform approach for producing inactivated vaccines using riboflavin-mediated photochemical inactivation with UVA/UVB irradiation, designed to preserve antigen presentation and be adaptable to multiple pathogens.
Photo-inactivation apparatus for vaccine production
Equipment and apparatus used to apply riboflavin and controlled UVA/UVB irradiation to biological material as part of the inactivation and vaccine production process.
Photochemical inactivated vaccine platform
A platform approach for producing inactivated vaccines using riboflavin-mediated photochemical inactivation with UVA/UVB irradiation, designed to preserve antigen presentation and be adaptable to multiple pathogens.
Photo-inactivation apparatus for vaccine production
Equipment and apparatus used to apply riboflavin and controlled UVA/UVB irradiation to biological material as part of the inactivation and vaccine production process.
Services
Photochemical vaccine platform R&D
Research and development of vaccines using photochemical inactivation methods that preserve antigen structure.
Preclinical efficacy testing and translational support
Design and execution of animal challenge studies, virology and histopathology assessments, and program activities to support advancement toward clinical testing.
Manufacturing process development and equipment design for photo-inactivated vaccines
Development of scalable manufacturing processes and apparatus for photochemical inactivation suited to decentralized and local production.
Program management for government-funded vaccine projects
Management and execution of research programs funded by government agencies, including grant administration and consortium participation.
Photochemical vaccine platform R&D
Research and development of vaccines using photochemical inactivation methods that preserve antigen structure.
Preclinical efficacy testing and translational support
Design and execution of animal challenge studies, virology and histopathology assessments, and program activities to support advancement toward clinical testing.
Manufacturing process development and equipment design for photo-inactivated vaccines
Development of scalable manufacturing processes and apparatus for photochemical inactivation suited to decentralized and local production.
Program management for government-funded vaccine projects
Management and execution of research programs funded by government agencies, including grant administration and consortium participation.
Expertise Areas
- Vaccine platform development using photochemical inactivation
- Preclinical vaccine evaluation and animal challenge studies
- Whole-virion vaccine formulation
- Decentralized and low-cost vaccine manufacturing strategies
Key Technologies
- Riboflavin (vitamin B2)-mediated photochemical inactivation
- UVA/UVB irradiation for nucleic acid modification
- Whole-virion vaccine approaches
- Animal challenge models